The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
Open accessAbstract
Obatoclax mesylate is a small molecule pan–Bcl-2 antagonist with in vitro activity against chronic lymphocytic leukemia (CLL) cells. Obatoclax was administered to patients with advanced CLL at doses ranging from 3.5 to 14 mg/m2 as a 1-hour infusion and from 20 to 40 mg/m2 as a 3-hour infusion every 3 weeks. Twenty-six patients received a total of 74 cycles. Dose-limiting reactions were neurologic (somnolence, euphoria, ataxia) and associated with the infusion. The maximum tolerated dose (MTD) was 28 mg/m2 over 3 hours every 3 weeks. One (4%) of 26 patients achieved a partial response. Patients with anemia (3/11) or thrombocytopenia (4/14) experienced improvements in hemoglobin and platelet counts. Circulating lymphocyte counts were reduced in 18 of 26 patients with a median reduction of 24%. Overall, the maximum plasma concentration (Cmax) and area under the curve (AUC) values of obatoclax were dose proportional. Activation of Bax and Bak was demonstrated in peripheral blood mononuclear cells, and induction of apoptosis was related to overall obatoclax exposure, as monitored by the plasma concentration of oligonucleosomal DNA/histone complexes. Obatoclax mesylate has biologic activity and modest single-agent activity in heavily pretreated patients with advanced CLL. Further evaluation in less heavily pretreated patients and in combination with other therapeutic agents is warranted. This trial has been registered with http://clinicaltrials.gov under identifier NCT00600964.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Cheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Self-citationNguyen, M., Marcellus, R. C., Roulston, A., Watson, M., Serfass, L., Murthy Madiraju, S. R., Goulet, D., Viallet, J., Bélec, L., Billot, X., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709443104 · Cited by 659
Self-citationKitada, S., Andersen, J., Akar, S., Zapata, J. M., Takayama, S., Krajewski, S., Wang, H.-G., Zhang, X., Bullrich, F., Croce, C. M., et al. (1998) · Blood · doi:10.1182/blood.v91.9.3379 · Cited by 651
Apoptosis-based therapies for hematologic malignancies
Reed, J. C., & Pellecchia, M. (2005) · Blood · doi:10.1182/blood-2004-07-2761 · Cited by 402
DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells
Cuconati, A., Mukherjee, C., Perez, D., & White, E. (2003) · Genes & Development · doi:10.1101/gad.1156903 · Cited by 315
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma
Trudel, S., Li, Z. H., Rauw, J., Tiedemann, R. E., Wen, X. Y., & Stewart, A. K. (2007) · Blood · doi:10.1182/blood-2006-10-047951 · Cited by 218
Pérez-Galán, P., Roué, G., Villamor, N., Campo, E., & Colomer, D. (2007) · Blood · doi:10.1182/blood-2006-07-034173 · Cited by 190
Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells
Jiang, N., Reich, C. F., & Pisetsky, D. S. (2003) · Blood · doi:10.1182/blood-2002-10-3312 · Cited by 97
Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells
Campàs, C., Cosialls, A. M., Barragán, M., Iglesias‐Serret, D., Santidrián, A. F., Coll-Mulet, L., de Frías, M., Domingo, A., Pons, G., & Gil, J. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.07.008 · Cited by 87
Cited by
Targeting mitochondria for cancer therapy
Fulda, S., Galluzzi, L., & Kroemer, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3137 · Cited by 1,629
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
Self-citationIndoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 636
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Metadata
- Authors
- O'Brien, S. M., Claxton, D. F., Crump, M., Faderl, S., Kipps, T., Keating, M. J., Viallet, J., & Cheson, B. D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-01-08
- Volume
- 113
- Issue
- 2
- Pages
- 299-305
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2013510617
- Cited by
- 274
- References
- 14
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. https://app.cochat.ai/papers/10.1182/blood-2008-02-137943
- The paper
- O'Brien, S. M., Claxton, D. F., Crump, M., Faderl, S., Kipps, T., Keating, M. J., Viallet, J., & Cheson, B. D. (2009). Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. https://doi.org/10.1182/blood-2008-02-137943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.